Evolent Health (EVH) Net Income towards Common Stockholders (2014 - 2026)

Evolent Health's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$26.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 63.14% year-over-year to -$26.6 million; the TTM figure through Mar 2026 stood at -$533.8 million (down 279.97% YoY), while the FY2025 annual figure was -$579.4 million, down 519.99% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$26.6 million, up from -$429.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.1 million in Q3 2022, with the low at -$429.1 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$26.9 million (2025), against an average of -$50.6 million.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders soared 116.28% in 2022, then tumbled 1663.64% in 2023.
• Evolent Health's Net Income towards Common Stockholders stood at -$11.3 million in 2022, then plunged by 264.75% to -$41.4 million in 2023, then increased by 26.04% to -$30.6 million in 2024, then slumped by 1301.7% to -$429.1 million in 2025, then jumped by 93.79% to -$26.6 million in 2026.
• Business Quant data shows EVH's Net Income towards Common Stockholders at -$26.6 million in Q1 2026, -$429.1 million in Q4 2025, and -$26.9 million in Q3 2025.